Efficacy of Two Levofloxacin‐Containing Second‐Line Therapies for <i><scp>H</scp>elicobacter pylori</i>: A Pilot Study

Çalhan, Turan; Kahraman, Resul; Şahin, Abdurrahman; Şenateş, Ebubekir; Doganay, Levent; Kanat, Evren; Özdil, Kamil; Sökmen, H. Mehmet

doi:10.1111/hel.12056

Cited by 15 publications

(15 citation statements)

References 36 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The city of Wuwei, located in northwest China, has a particularly high incidence of gastric cancer (91.18/ 100,000 from 2001 to 2002) [17]. According to research conducted in children and teenagers, the infection rate of H. pylori in 2006-2007 was as high as 72.3% (678/938) in Wuwei. Similar results were also been identified in Linyu and Changle in the last century.…”

Section: Epidemiologymentioning

confidence: 99%

“…Levofloxacin-containing therapy was designed to overcome the shortage of clarithromycin for standard triple therapy and was recommended as a second-line therapy in the Maastricht IV/Florence consensus report [38]. In Western countries, resistance to levofloxacin was low [65,68,69], and it was found that levofloxacin triple therapy could effectively eradicate H. pylori in these countries [65,[70][71][72]. However, the prevalence and the rate of antibiotic resistance of H. pylori in China are quite different from those in Western countries.…”

Section: Levofloxacin-containing Therapymentioning

confidence: 99%

See 1 more Smart Citation

Review: Clinical Management of Helicobacter pylori Infection in China

Xie

Lü

2014

Helicobacter

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) infection has been associated with gastric disorders. The situation of H. pylori infection in China-where a high prevalence of H. pylori infection, a high incidence of gastric cancer, and widespread resistance to clarithromycin, metronidazole, and levofloxacin exist-is quite different from that in Western countries. In order for Chinese clinicians to better manage H. pylori infection, a Chinese Study Group on H. pylori published four consensus reports regarding the management of H. pylori infection in China between 1999 and 2012. The eradication rate with standard triple therapy was <80% in most areas of China. Bismuth is available in China, and bismuth-containing quadruple therapy has been shown to produce a high eradication rate; thus, bismuth quadruple therapy could be recommended both as an initial and as a rescue therapy in China. There is no advantage of sequential therapy over triple therapy in Chinese patients, but the efficacy of concomitant therapy must be studied further. This review introduces the epidemiology, diagnosis, indicators, and therapies for the eradication of H. pylori in China in recent years.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Levofloxacin-containing Therapymentioning

confidence: 99%

Review: Clinical Management of Helicobacter pylori Infection in China

Xie

Lü

2014

Helicobacter

View full text Add to dashboard Cite

show abstract

“…There have been considerable reports of the successful efficacy of fluoroquinolones, such as levofloxacin or moxifloxacin, in combination with PPI and amoxicillin in the treatment of H. pylori infection, both as the first-line and second-line treatment [34][35][36]. Recently, a few trials evaluating the eradication rate of a levofloxacin-containing sequential regimen in the eradication of H. pylori-infected patients were presented [25,[37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea

Lee

Hong

Min

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

“…This reduction stimulated searches for new treatment protocols. In Turkey, this rate was found to have decreased to 55.7% [9,17].…”

Section: Epidemiologymentioning

confidence: 99%

Helicobacter Pylori Treatment in Turkey: Current Status and Rational Treatment Options

Kaplan¹,

Tanoğlu²,

Düzenli³

et al. 2019

North Clin Istanbul

View full text Add to dashboard Cite

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations for rational therapeutic considerations for the eradication of the bacterium.

show abstract

Efficacy of Two Levofloxacin‐Containing Second‐Line Therapies for Helicobacter pylori: A Pilot Study

Cited by 15 publications

References 36 publications

Review: Clinical Management of Helicobacter pylori Infection in China

Review: Clinical Management of Helicobacter pylori Infection in China

Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea

Helicobacter Pylori Treatment in Turkey: Current Status and Rational Treatment Options

Contact Info

Product

Resources

About